Safety and Tolerability of High-Dosage Coenzyme Q10 in Huntington's Disease and Healthy Subjects
Identifieur interne : 001F15 ( Main/Exploration ); précédent : 001F14; suivant : 001F16Safety and Tolerability of High-Dosage Coenzyme Q10 in Huntington's Disease and Healthy Subjects
Auteurs :Source :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Coenzyme Q10 (CoQ10), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/ day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ10 dosages may prove beneficial. We investigated the tolerability and blood levels associated with 1,200, 2,400, and 3,600 mg/day of CoQ10 in HD and healthy subjects. Twenty-eight subjects (20 HD, 8 healthy) enrolled in a 20-week open-label trial. Subjects started on 1,200 mg/day of CoQ10, increasing every 4 weeks by 1,200 mg to a maximum dosage of 3,600 mg/day. Monthly evaluations included review of adverse events and CoQ10 blood levels. Twenty-three subjects (82%) achieved the target dosage of 3,600 mg/day. Six subjects (2 healthy, 4 HD) withdrew prematurely (gastrointestinal (GI) symptoms in 3, worsening HD in 2, and 1 because of a fall). All three serious adverse events occurred in a single subject, and were deemed unrelated to CoQ10. The most common adverse events seen were GI symptoms. Mean (± SD) CoQ10 blood levels achieved over the course of the trial were as follows: 1.26 ± 1.27 μg/mL (baseline, n = 28), 5.59 ± 2.24 μg/mL (1,200 mg/day, week 4, n = 26), 6.38 ± 3.25 μg/mL (2,400 mg/day, week 8, n = 25), 7.49 ± 4.09 μg/mL (3,600 mg/day, week 12, n = 23), and 6.78 ± 3.36 μg/mL (3,600 mg/day, week 20, n = 20). CoQ10 was well tolerated with over 80% of subjects achieving the target dosage. Dosages of 2,400 mg/day may provide the best balance between tolerability and blood level achieved. Further studies examining the efficacy of 2,400 mg/day are planned.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000910
- to stream PascalFrancis, to step Curation: 002409
- to stream PascalFrancis, to step Checkpoint: 000848
- to stream Main, to step Merge: 002435
- to stream Main, to step Curation: 001F15
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Safety and Tolerability of High-Dosage Coenzyme Q<sub>10</sub> in Huntington's Disease and Healthy Subjects</title></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0446323</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0446323 INIST</idno><idno type="RBID">Pascal:10-0446323</idno><idno type="wicri:Area/PascalFrancis/Corpus">000910</idno><idno type="wicri:Area/PascalFrancis/Curation">002409</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000848</idno><idno type="wicri:Area/Main/Merge">002435</idno><idno type="wicri:Area/Main/Curation">001F15</idno><idno type="wicri:Area/Main/Exploration">001F15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Safety and Tolerability of High-Dosage Coenzyme Q<sub>10</sub> in Huntington's Disease and Healthy Subjects</title></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Healthy subject</term><term>Huntington disease</term><term>Nervous system diseases</term><term>Safety</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chorée de Huntington</term><term>Pathologie du système nerveux</term><term>Sécurité</term><term>Individu sain</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coenzyme Q10 (CoQ<sub>10</sub>), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/ day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ<sub>10</sub> dosages may prove beneficial. We investigated the tolerability and blood levels associated with 1,200, 2,400, and 3,600 mg/day of CoQ<sub>10</sub> in HD and healthy subjects. Twenty-eight subjects (20 HD, 8 healthy) enrolled in a 20-week open-label trial. Subjects started on 1,200 mg/day of CoQ<sub>10</sub>, increasing every 4 weeks by 1,200 mg to a maximum dosage of 3,600 mg/day. Monthly evaluations included review of adverse events and CoQ<sub>10</sub> blood levels. Twenty-three subjects (82%) achieved the target dosage of 3,600 mg/day. Six subjects (2 healthy, 4 HD) withdrew prematurely (gastrointestinal (GI) symptoms in 3, worsening HD in 2, and 1 because of a fall). All three serious adverse events occurred in a single subject, and were deemed unrelated to CoQ<sub>10</sub>. The most common adverse events seen were GI symptoms. Mean (± SD) CoQ10 blood levels achieved over the course of the trial were as follows: 1.26 ± 1.27 μg/mL (baseline, n = 28), 5.59 ± 2.24 μg/mL (1,200 mg/day, week 4, n = 26), 6.38 ± 3.25 μg/mL (2,400 mg/day, week 8, n = 25), 7.49 ± 4.09 μg/mL (3,600 mg/day, week 12, n = 23), and 6.78 ± 3.36 μg/mL (3,600 mg/day, week 20, n = 20). CoQ<sub>10</sub> was well tolerated with over 80% of subjects achieving the target dosage. Dosages of 2,400 mg/day may provide the best balance between tolerability and blood level achieved. Further studies examining the efficacy of 2,400 mg/day are planned.</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:10-0446323
|texte= Safety and Tolerability of High-Dosage Coenzyme Q10 in Huntington's Disease and Healthy Subjects
}}
| This area was generated with Dilib version V0.6.23. |  |